Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017, 23(14):3756-3768. Alisertib (MLN8237) purchased from Selleck.

    Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

  • Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

    Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
1.2 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 M2fwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXewMlUh|ryP M4X2fVczKGh? NUj0bFBLTE2VTx?= NFLwUlRKSzVyPUCuNFQh|ryP M1v1V|I3OTN4Nki0
LS174T MoLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPjXFIzOC53IN88US=> MWG3NkBp NWDDUmhrTE2VTx?= NGLKWWJKSzVyPUCuNFUh|ryP NYPEVlZ7OjZzM{[2PFQ>
T84 MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe1Z5kxNjVizszN NYfHbHZkPzJiaB?= M1TPcGROW09? MknPTWM2OD1yLkC5JO69VQ>? NVTlVVhLOjZzM{[2PFQ>
LS180 Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf6[HRMOC53IN88US=> MXi3NkBp Mo\3SG1UVw>? NGm1c3dKSzVyPUGg{txO NUj0UnRbOjZzM{[2PFQ>
SW948 NEGyeWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi2OoNiOC53IN88US=> Mkj1O|IhcA>? NIi5V|NFVVOR NYfjOpFRUUN3ME2xJO69VQ>? MkT0NlYyOzZ4OES=
HCT15 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LBXlAvPSEQvF2= MYO3NkBp NEH0WXJFVVOR NEDXZW5KSzVyPECuOEDPxE1? MmfxNlYyOzZ4OES=
DLD-1 NFzuVY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[wMlUh|ryP MWC3NkBp MX\EUXNQ MnXOTWM2ODxyLkig{txO MUKyOlE{PjZ6NB?=
MIP-101 NG[z[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYmwMlUh|ryP NGnvTG84OiCq NXrTfVB5TE2VTx?= NFHXe|BKSzVyPUGg{txO M3y5blI3OTN4Nki0
SNU1544 MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;VNE42KM7:TR?= NE\DXI84OiCq NFrHbGVFVVOR M3XmZWlEPTB;MTFOwG0> NXfhW3NyOjZzM{[2PFQ>
OCI-Ly10 Mk\sR5l1d3SxeHnjJGF{e2G7 NIDENoo4OiCq MXXEUXNQ MlfpTWM2OD1yLkC1PEDPxE1? NV\JZ2VGOjV6N{izN|E>
SU-DHL2 NFrqWXVEgXSxdH;4bYMhSXO|YYm= NH7oe3M4OiCq Ml[3SG1UVw>? MoTBTWM2OD1yLkCxJO69VQ>? NIjqRoUzPTh5OEOzNS=>
OCI-LY7 M3[zTGN6fG:2b4jpZ{BCe3OjeR?= MWG3NkBp NH7nWVdFVVOR MlSxTWM2OD1yLkC4NUDPxE1? M2n3XFI2QDd6M{Ox
SU-DHL6 M4ixXWN6fG:2b4jpZ{BCe3OjeR?= NYn2W2ROPzJiaB?= M3z1[WROW09? NETEXGZKSzVyPUCuOFgzKM7:TR?= MYCyOVg4QDN|MR?=
Jeko-1 MUHDfZRwfG:6aXOgRZN{[Xl? MWm3NkBp MY\EUXNQ NEPDT|FKSzVyPUCuNFI6KM7:TR?= M4XVV|I2QDd6M{Ox
JVM-2 NXPtR29LS3m2b4TvfIlkKEG|c3H5 MWe3NkBp MU\EUXNQ MmLjTWM2OD1yLkCxJO69VQ>? MlTwNlU5Pzh|M{G=
Rec-1 MVLDfZRwfG:6aXOgRZN{[Xl? MlfZO|IhcA>? M{XOcGROW09? MofqTWM2OD1yLkC4O{DPxE1? MXyyOVg4QDN|MR?=
Z-138 M2jXbmN6fG:2b4jpZ{BCe3OjeR?= MVy3NkBp NXK4TVJrTE2VTx?= MlXsTWM2OD1yLkCxN{DPxE1? MoTlNlU5Pzh|M{G=
H9 M3TNOWN6fG:2b4jpZ{BCe3OjeR?= NHnKPVM4OiCq NEPFcIZFVVOR MUPJR|UxRTBwNjFOwG0> M4rtfVI2QDd6M{Ox
HH MoPrR5l1d3SxeHnjJGF{e2G7 MkLIO|IhcA>? MVTEUXNQ M4fWN2lEPTB;MD63JO69VQ>? M3\IN|I2QDd6M{Ox
DND41 NYPNTllRS3m2b4TvfIlkKEG|c3H5 NULaUIVPPzJiaB?= MXPEUXNQ NUS4b5RiUUN3ME2wMlEh|ryP NHfiSW8zPTh5OEOzNS=>
CCL119 M1rwbWN6fG:2b4jpZ{BCe3OjeR?= M3TSVVczKGh? M3PNTGROW09? NVrZcYZzUUN3ME2wMlA3OiEQvF2= NWrPd3VMOjV6N{izN|E>
J.Cam 1.6 NXG5NFZ[S3m2b4TvfIlkKEG|c3H5 M4j2[FczKGh? M{i1dGROW09? M{XQZWlEPTB;MD6xNFUh|ryP NWr2flYyOjV6N{izN|E>
Sup-T1 Mnu5R5l1d3SxeHnjJGF{e2G7 NELkUW84OiCq NH\DV3NFVVOR MnOxTWM2OD1{LkG0NkDPxE1? NEHIcI4zPTh5OEOzNS=>
Tib 152 NVTVbXlLS3m2b4TvfIlkKEG|c3H5 MWS3NkBp NFnQW4lFVVOR MWjJR|UxRTBwODFOwG0> NGXwZ4ozPTh5OEOzNS=>
MCF7 MoDtSpVv[3Srb36gRZN{[Xl? MWK1JO69VQ>? M13h[lI1KGh? NHrpdlJFVVOR Ml23TY5lfWOnczDHNk9OKGG{cnXzeC=> MWOyOVg{PDRyMR?=
MDA-MB-231 M3O1fWZ2dmO2aX;uJGF{e2G7 NFuyUZU2KM7:TR?= MV2yOEBp M1jkSWROW09? MmnrTY5lfWOnczDHN{9OKGG{cnXzeC=> NXfPWIZ[OjV6M{S0NFE>
MCF7 Mn;hSpVv[3Srb36gRZN{[Xl? MXS1JO69VQ>? NHS4UGkzPCCq M{LIWmROW09? MnHNSIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET|EwS0SFMh?= MUOyOVg{PDRyMR?=
MCF7 MlzWSpVv[3Srb36gRZN{[Xl? Ml[5OUDPxE1? NWr4Z|c{OjRiaB?= NYP6bJo{TE2VTx?= M4D2N2Rm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz NUnKbWQ1OjV6M{S0NFE>
MCF7 MknwSpVv[3Srb36gRZN{[Xl? MYW1JO69VQ>? M3LpR|I1KGh? MojKSG1UVw>? NGPZNXhF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx NUj2elBFOjV6M{S0NFE>
MCF7 MX7GeY5kfGmxbjDBd5NigQ>? Mn7YOUDPxE1? NGTMPJYzPCCq NUPVUJhsTE2VTx?= NFTQeHdKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFIyKFejZkGvR4lxOQ>? M3m5eFI2QDN2NECx
MCF7 NF\mfXVHfW6ldHnvckBCe3OjeR?= M4r5RlUh|ryP NXHGXXp1OjRiaB?= MV;EUXNQ MoHDTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyO{BMcXBz M1ezZVI2QDN2NECx
MDA-MB-231 MXnGeY5kfGmxbjDBd5NigQ>? NETzT5o2KM7:TR?= MkHINlQhcA>? NUXiWGtZTE2VTx?= NGXVWmFF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy NXXxZm5POjV6M{S0NFE>
MDA-MB-231 Mle5SpVv[3Srb36gRZN{[Xl? NXSwO|dwOSEQvF2= MlGwNlQhcA>? NF\ifJhFVVOR NF62[WxKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOg>? MWCyOVg{PDRyMR?=
MDA-MB-231 Ml3SSpVv[3Srb36gRZN{[Xl? MUG1JO69VQ>? NV3XcmtlOjRiaB?= Mon1SG1UVw>? NEXUXW1F\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx NXvZR4E4OjV6M{S0NFE>
MDA-MB-231 NXiwUGJ3TnWwY4Tpc44hSXO|YYm= NEey[nc2KM7:TR?= NF35c3EzPCCq MX;EUXNQ NV;v[YsyUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzOSCZYX[xM2NqeDF? MoHWNlU5OzR2MEG=
MDA-MB-231 MX;GeY5kfGmxbjDBd5NigQ>? MWO1JO69VQ>? M1fDRVI1KGh? MmrySG1UVw>? MULJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEK3JGtqeDF? M2PTU|I2QDN2NECx
MDA-MB-231 MWXGeY5kfGmxbjDBd5NigQ>? NEPnUYg2KM7:TR?= NWrMNWh5OjRiaB?= M4rOU2ROW09? MojPTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIIC1Ny=> M2TOXFI2QDN2NECx
MCF7 MmnDRZBweHSxc3nzJGF{e2G7 NXGyU|huPSEQvF2= MlTINlQhcA>? MW\EUXNQ MVPJcoR2[2W|IHHwc5B1d3SrYzDk[YF1cA>? NEHPWIQzPTh|NESwNS=>
MDA-MB-231 NF3QW4RCeG:ydH;zbZMhSXO|YYm= M3vaUVUh|ryP NFnON24zPCCq NF7iTWJFVVOR M2TxUWlv\HWlZYOgZZBweHSxdHnjJIRm[XSq MWiyOVg{PDRyMR?=
MCF7 NFzjeIZHfW6ldHnvckBCe3OjeR?= MVOxJO69VQ>? MoHTO|IhcA>? NYXY[oZ3TE2VTx?= NEHne2xKdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi= M4flZ|I2QDN2NECx
MDA-MB-231 MlzvSpVv[3Srb36gRZN{[Xl? MkfpNUDPxE1? M1Xk[|czKGh? M1r6ZWROW09? M4PFdGlv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?= MWKyOVg{PDRyMR?=
U-2 OS NW\TdFVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTzR5k2OCEQvF2= M4HFSFI1KGh? NH3YVodFVVOR NYfJTHhiUUN3ME2xOk43KM7:TR?= NWfQOFJpOjV5OUK4NVE>
MG-63 NFn5eXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXkOVAh|ryP Ml7XNlQhcA>? NWXJPY9sTE2VTx?= Mn\FTWM2OD17LkWg{txO MoTjNlU4QTJ6MUG=
U-2 OS MY\BdI9xfG:|aYOgRZN{[Xl? M2GwTVUh|ryP NXLFZm5FOjRiaB?= NHn1TZZFVVOR MW\JcoR2[2W|IHHwc5B1d3SrYzDj[YxtKGSnYYTo Mom1NlU4QTJ6MUG=
MG-63 NWXVUpJbSXCxcITvd4l{KEG|c3H5 MYW1JO69VQ>? M2fyOVI1KGh? NEP5Sm1FVVOR MUfJcoR2[2W|IHHwc5B1d3SrYzDj[YxtKGSnYYTo MlKyNlU4QTJ6MUG=
U-2 OS MWXGeY5kfGmxbjDBd5NigQ>? NUfEN|VJPSEQvF2= Mk\lNlQhcA>? NYXpUHV5TE2VTx?= NET6bW5Rem:vb4Tld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? M3XKfVI2Pzl{OEGx
MG-63 M2jxdWZ2dmO2aX;uJGF{e2G7 MmnzOUDPxE1? NI\5cYUzPCCq NXHGbHUxTE2VTx?= NVu4W2RGWHKxbX;0[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq Ml\INlU4QTJ6MUG=
PANC-1 Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXYOVAh|ryP NFvRfI4zPCCq MWLEUXNQ Mmr5TWM2OD15LkGg{txO MnPCNlU3OzJ{MkW=
BxPC-3 NIrhbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXWV5k2OCEQvF2= MoK0NlQhcA>? NUXZdGl6TE2VTx?= MkX0TWM2OD14Lkig{txO NEH3WmEzPTZ|MkKyOS=>
PANC-1 NVLWPIVoTnWwY4Tpc44hSXO|YYm= NHPMSGE2KM7:TR?= NWXY[2VJOjRiaB?= MoPwSG1UVw>? NYfVeolUUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiCJMj;NJJBp[XOn MnTUNlU3OzJ{MkW=
BxPC-3 M1ywOGZ2dmO2aX;uJGF{e2G7 NGLYRVk2KM7:TR?= MoHSNlQhcA>? M1jZdGROW09? M2HGcmlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hTzJxTTDwbIF{\Q>? NF7mU20zPTZ|MkKyOS=>
PANC-1 M3nvVGZ2dmO2aX;uJGF{e2G7 NUK5W45[PSEQvF2= NFXZS40zPCCq NGPsdFJFVVOR NE\DbpVKdmS3Y3XzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? Mo\yNlU3OzJ{MkW=
BxPC-3 NEH0XWVHfW6ldHnvckBCe3OjeR?= M{fZRlUh|ryP M1jPOVI1KGh? MoXDSG1UVw>? NVHQXXptUW6mdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? NXL3SFJZOjV4M{KyNlU>
SKOV3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;KNVAxKM7:TR?= MXyyOEBp M4fBcWROW09? Mnr0TWM2OD1{MD60PEDPxE1? Ml;FNlU3OjR5NUC=
OVCAR4 M1mwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmxNFAh|ryP M4n2NlI1KGh? NV7RR3RXTE2VTx?= MkDSTWM2OD1{Mj6xN{DPxE1? NHzhSokzPTZ{NEe1NC=>
SKOV3 MlHrSpVv[3Srb36gRZN{[Xl? MVW1JO69VQ>? Ml7mO|IhcA>? MkTDSG1UVw>? NXHrR|VsUW6mdXPld{BIOi:PIHHydoV{fA>? NYjhTIg{OjV4MkS3OVA>
OVCAR4 MWrGeY5kfGmxbjDBd5NigQ>? M3\UfVUh|ryP M3HHcVczKGh? MX7EUXNQ MnGwTY5lfWOnczDHNk9OKGG{cnXzeC=> MW[yOVYzPDd3MB?=
SKOV3 MnrURZBweHSxc3nzJGF{e2G7 MnTSOUDPxE1? MUiyOEBp M4[5cmROW09? NGjwfJJKdmS3Y3XzJIFxd3C2b4Ppdy=> MoHGNlU3OjR5NUC=
OVCAR4 MVjBdI9xfG:|aYOgRZN{[Xl? NF\OXng2KM7:TR?= MmPzNlQhcA>? M4GxUGROW09? NXjXZnN{UW6mdXPld{BieG:ydH;zbZM> MljGNlU3OjR5NUC=
AGS Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\KSVI2KM7:TR?= M4PiOFI1KGh? MUPEUXNQ MkX3TWM2OD1zOT6wPUDPxE1? MX:yOVYxQTl{Mx?=
NCI-N78 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLqNlUh|ryP M{XLZ|I1KGh? MX\EUXNQ M{nk[2lEPTB;Mk[uN|Mh|ryP NUWwR3JiOjV4MEm5NlM>
AGS NXvlZXJ6SXCxcITvd4l{KEG|c3H5 NH6y[nc2KM7:TR?= Mmr0NlQhcA>? NGiwWGZFVVOR NVXke|c4UW6mdXPld{BieG:ydH;zbZM> MmCwNlU3ODl7MkO=
NCI-N78 MY\BdI9xfG:|aYOgRZN{[Xl? NXfnW4s6PSEQvF2= MXqyOEBp MWPEUXNQ NFfLSnlKdmS3Y3XzJIFxd3C2b4Ppdy=> MYKyOVYxQTl{Mx?=
AGS NYH2OIJNTnWwY4Tpc44hSXO|YYm= MmnsOUDPxE1? Ml21NlQhcA>? NWTRXY1FTE2VTx?= M3TvSmlv\HWlZYOgeIhmKGG3dH;wbIFogQ>? NGP0T28zPTZyOUmyNy=>
NCI-N78 NVTVXWtzTnWwY4Tpc44hSXO|YYm= NY\j[phVPSEQvF2= NEjsS5EzPCCq M1:zOWROW09? NFz3WHlKdmS3Y3XzJJRp\SCjdYTvdIhi\3l? MWOyOVYxQTl{Mx?=
HSC-3 NFnHSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:zNFEh|ryP M1rxOVQ5KGh? MUHJR|UxRTBwNUSg{txO NIXuZYwzPTN4NkG0Ny=>
GB30 NIjGOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:xJO69VQ>? Ml30O{Bl MWPEUXNQ Mn34TWM2OD1yLkCxNUDPxE1? M4S1NlI2OTB4NEK4
GB9 MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3jOWR6OSEQvF2= MYW3JIQ> M2Dod2ROW09? MV;JR|UxRTBwMEK0JO69VQ>? M1;aO|I2OTB4NEK4
GB169 NWHT[YF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3BNUDPxE1? MX:3JIQ> MkLpSG1UVw>? MlXzTWM2OD1yLkCzNkDPxE1? NXPVV4VLOjVzME[0Nlg>
T24 NFXCOVJHfW6ldHnvckBCe3OjeR?= NXGzW5ZLOSEQvF2= NVTnUm9[PDhiaB?= MUTEUXNQ Ml22TY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= NEP4RVczOzRyM{[zNy=>
RT4 NHT2VVNHfW6ldHnvckBCe3OjeR?= MV:xJO69VQ>? NIe2Now1QCCq MXXEUXNQ NEjtRYFKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 MVeyN|QxOzZ|Mx?=
UM-UC-3 MVjGeY5kfGmxbjDBd5NigQ>? M3viUFEh|ryP NVSxWWFHPDhiaB?= NIruUmFFVVOR MWTJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 M2TNcVI{PDB|NkOz
T24 NWDkPIZ7SXCxcITvd4l{KEG|c3H5 MoDnN{4yPiEQvF2= NG\PRWs6PiCq MYLEUXNQ NFTE[GdKSzVyPUCuNFMxPiEQvF2= NInOXI4zOzRyM{[zNy=>
RT4 Ml7lRZBweHSxc3nzJGF{e2G7 MWWzMlE3KM7:TR?= MUS5OkBp M1Pk[2ROW09? M{C5fWlEPTB;MD6xNVk5KM7:TR?= M3zoZlI{PDB|NkOz
UM-UC-3 NHT4UFhCeG:ydH;zbZMhSXO|YYm= NIj2bXg{NjF4IN88US=> MnXRPVYhcA>? Mnm4SG1UVw>? MoHtTWM2OD1yLkC0OFkh|ryP NEfUeZUzOzRyM{[zNy=>
OVCAR-5 NXXXTIlMTnWwY4Tpc44hSXO|YYm= M1T2RlUxKG6P NYriTJFIUW6qaXLpeJMh[2WubDDtbYdz[XSrb36= NIHoNlQzOzN|NEOyOy=>
SKOV3ip2 MmfCSpVv[3Srb36gRZN{[Xl? NUPWU48zPTBibl2= M4r1eWlvcGmkaYTzJINmdGxibXnndoF1cW:w NHG1fWczOzN|NEOyOy=>
S462 NHLLNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TiUFExOCEQvF2= NIPkXGI4OiCq MnjSSG1UVw>? MX3BeJRmdnWjdHXzJINmdGxiZ4Lve5Rp MVuyN|MzQDFzNB?=
2884 NYfZUIx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOxNFAh|ryP M2DDW|czKGh? MX3EUXNQ MmLaRZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? M{SxWVI{OzJ6MUG0
2885 MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6xNFAh|ryP MYS3NkBp NIHWdlRFVVOR MU\BeJRmdnWjdHXzJINmdGxiZ4Lve5Rp MoDrNlM{OjhzMUS=
CRL-2396 NVjvUmR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknQNVAxKM7:TR?= NGHveZp4[XSnch?= MVLJR|UxRTBwMEmyJO69VQ>? MVGyN|E2OzV{NB?=
TIB-48 MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL2OnRNOTByIN88US=> NGrWbnl4[XSnch?= M2rYR2lEPTB;MD6wPFgh|ryP M3HEflI{OTV|NUK0
CRL-2396 MYfDfZRwfG:6aXOgRZN{[Xl? NWK0O5hnOSEQvF2= M17PcFQ5KGh? MXv3ZZRmeg>? NXy1c4VPUW6mdXPld{BieG:ydH;zbZM> M4P1NFI{OTV|NUK0
TIB-48 NYK4dHhZS3m2b4TvfIlkKEG|c3H5 MV:xJO69VQ>? MlLaOFghcA>? MYT3ZZRmeg>? NG\DS4xKdmS3Y3XzJIFxd3C2b4Ppdy=> NGn4WJUzOzF3M{WyOC=>
AGS NF[5OGREgXSxdH;4bYMhSXO|YYm= MVywMlUh|ryP NXTqR5lDOjRiaB?= MYrEUXNQ NH\tSZBF\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?= M2TEV|IzQTd{NkGx
FLO-1 MmPFR5l1d3SxeHnjJGF{e2G7 M{nlNlAvPSEQvF2= NYLzWI1mOjRiaB?= M{\LTGROW09? M1r2e2Rm[3KnYYPld{Bk\WyuIIP1dpZqfmGu NUPUflRQOjJ7N{K2NVE>
OE33 NV7FU3c6S3m2b4TvfIlkKEG|c3H5 MYCwMlUh|ryP NVz5UXl[OjRiaB?= NFvZVpBFVVOR NWPQS25VTGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy= M163SlIzQTd{NkGx
SKLMS NGrESIREgXSxdH;4bYMhSXO|YYm= MXi3OUBvVQ>? M1\LVVk3KGh? NU\FdnBKUW6mdXPld{BieG:ydH;zbZM> Mn\LNlI5OjF7OUe=
Leio285 MmfRR5l1d3SxeHnjJGF{e2G7 NGK0eoY4PSCwTR?= NHXITXc6PiCq NHHRXnRKdmS3Y3XzJIFxd3C2b4Ppdy=> NIDjW40zOjh{MUm5Oy=>
Mes-Sa NYDCU3B7S3m2b4TvfIlkKEG|c3H5 NYjORmxZPzVibl2= NXKyfJhlQTZiaB?= MYHJcoR2[2W|IHHwc5B1d3Orcx?= NHLVdGwzOjh{MUm5Oy=>
DAOY MUPDfZRwfG:6aXOgRZN{[Xl? M4raV|ExKM7:TR?= M1q3WlczKGh? NGrXTIhFVVOR MUnJR|UxRTBwMESg{txO NVT5fVdjOjJ4NkmzN|U>
IMR32 NFP5cGREgXSxdH;4bYMhSXO|YYm= M1HJTlExKM7:TR?= M3LYSlczKGh? MUTEUXNQ NIjZOJNKSzVyPUCuNFMh|ryP NGLIPZczOjZ4OUOzOS=>
Molt-4 M4e3[WN6fG:2b4jpZ{BCe3OjeR?= MUGxNEDPxE1? NXfDdZpYPzJiaB?= M1\J[mROW09? M3LLTmlEPTB;MD6wNkDPxE1? NEHiNYEzOjZ4OUOzOS=>
MOLM-13 NXjROINPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfzSVQ{KM7:TR?= NEDOVo84OiCq NVT1Ro84TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> M1f5cVIzPDh6MkS5
HL-60 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUezJO69VQ>? MkHsO|IhcA>? MUTEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NF3nTHUzOjR6OEK0PS=>
MV4-11 M{jHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjJOng{KM7:TR?= MYC3NkBp MWDEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NYTnVXJ3OjJ2OEiyOFk>
SKM-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nUdlMh|ryP MofvO|IhcA>? MVXEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 MnjENlI1QDh{NEm=
SH2 NIW0XFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXezJO69VQ>? MmKyO|IhcA>? Mn3LSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NVfPcWZLOjJ2OEiyOFk>
NOMO-1 M2r0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLXN{DPxE1? MnLNO|IhcA>? NGnxTGJFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 MoLCNlI1QDh{NEm=
OCL-AML2 NYTjeZNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInNeGs{KM7:TR?= M1jlSlczKGh? MYrEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NYqwRXdDOjJ2OEiyOFk>
PL-21 NIX6RY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml24N{DPxE1? M2SwSVczKGh? MmnWSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NX\4RphPOjJ2OEiyOFk>
KG-1 MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCzJO69VQ>? M3rDXVczKGh? NEjZOmhFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 MoOwNlI1QDh{NEm=
A172 MofuR5l1d3SxeHnjJGF{e2G7 MlTzNVAxKM7:TR?= NWH3WI9VOjRiaB?= MU\EUXNQ MXrJR|UxRTBwMUKwJO69VQ>? MlK2NlIzPzR|OUm=
U87 MYrDfZRwfG:6aXOgRZN{[Xl? MYexNFAh|ryP NEfsTFYzPCCq M{KyeWROW09? MnPCTWM2OD1yLkGwOUDPxE1? NGfaeoszOjJ5NEO5PS=>
U251 M{HZTWN6fG:2b4jpZ{BCe3OjeR?= MnT5NVAxKM7:TR?= MWCyOEBp MVjEUXNQ NHHKXJFKSzVyPUCuNVAxKM7:TR?= M1H2SFIzOjd2M{m5
T98 M2X5[2N6fG:2b4jpZ{BCe3OjeR?= MYmxNFAh|ryP NVz2c41nOjRiaB?= NVO3RVNPTE2VTx?= M3LUemlEPTB;MD6xNlUh|ryP MVyyNlI4PDN7OR?=
LN18 Mkn3R5l1d3SxeHnjJGF{e2G7 NHKxWVQyODBizszN MkXGNlQhcA>? MkLtSG1UVw>? M33Md2lEPTB;MD6yNVAh|ryP MUKyNlI4PDN7OR?=
LN443 MlmyR5l1d3SxeHnjJGF{e2G7 Mom1NVAxKM7:TR?= MkjCNlQhcA>? NWnBRXpsTE2VTx?= NXTXTIkzUUN3ME2wMlIzOCEQvF2= MV:yNlI4PDN7OR?=
HF66 MVXDfZRwfG:6aXOgRZN{[Xl? NUDyTmk5OTByIN88US=> NH21SnAzPCCq MonySG1UVw>? NHflWo9KSzVyPUCuNlI2KM7:TR?= NHfnfJgzOjJ5NEO5PS=>
HF2303 NILYTJJEgXSxdH;4bYMhSXO|YYm= M3;5[lExOCEQvF2= NUTITZlWOjRiaB?= M3vL[2ROW09? MkDtTWM2OD1yLkC2NEDPxE1? NGD6XXczOjJ5NEO5PS=>
HF2359 M174PGN6fG:2b4jpZ{BCe3OjeR?= M1G1[FExOCEQvF2= NHToc|QzPCCq M4jISmROW09? NYLNNWplUUN3ME2wMlA3OCEQvF2= MV2yNlI4PDN7OR?=
HF2414 NGjRV41EgXSxdH;4bYMhSXO|YYm= MUGxNFAh|ryP MYCyOEBp NUnGNJZXTE2VTx?= MV3JR|UxRTBwMEiwJO69VQ>? MX2yNlI4PDN7OR?=
A-673 Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrRfGoyOCEQvF2= MV25OkBp NVThOW5YTE2VTx?= MXrJR|UxRTBwMEOyJO69VQ>? M1Hv[VIyPDR6NUmx
TC-32 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n5RVExKM7:TR?= M1\zUFk3KGh? MmD5SG1UVw>? MXLJR|UxRTBwMEO5JO69VQ>? M1excVIyPDR6NUmx
TC-71 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rrVVExKM7:TR?= MmK0PVYhcA>? M32zc2ROW09? NXzIXYJoUUN3ME2wMlExOiEQvF2= NHHYNVAzOTR2OEW5NS=>
SK-N-MC MonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrYTGtQOTBizszN NHfDVVI6PiCq Mk\lSG1UVw>? NXvBe3RZUUN3ME2wMlA4OiEQvF2= M2SyV|IyPDR6NUmx
CHLA-9 M3zV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX2xNEDPxE1? NVfMTHAzQTZiaB?= NHrib4pFVVOR NG\1R2xKSzVyPUCuNFE5KM7:TR?= NFXDXpAzOTR2OEW5NS=>
CHLA-10 MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7KTGwyOCEQvF2= NIPINmk6PiCq MlfDSG1UVw>? NFnWfYtKSzVyPUCuNFYxKM7:TR?= NHTjNnQzOTR2OEW5NS=>
CHLA-25 NXjF[XNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj5RZlHOTBizszN MmX2PVYhcA>? MUXEUXNQ NFfsdZlKSzVyPUCuNVY5KM7:TR?= MkThNlE1PDh3OUG=
CHLA-32 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLrXW8yOTBizszN MU[5OkBp NE\yWYJFVVOR MXTJR|UxRTBwMUO2JO69VQ>? MoL5NlE1PDh3OUG=
CHLA-56 NEf3cm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS4NVAh|ryP MWC5OkBp MWjEUXNQ MXTJR|UxRTFyIN88US=> M4XXdVIyPDR6NUmx
CHLA-258 NI\mfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\FW|ExKM7:TR?= MWq5OkBp Ml;3SG1UVw>? NXjuRpJZUUN3ME2wMlE{OiEQvF2= MkHKNlE1PDh3OUG=
COG-E-352 NIHYPI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnUSWtkOTBizszN MYi5OkBp MXfEUXNQ NIXBWWpKSzVyPUCuNFQ{KM7:TR?= NHvUN3AzOTR2OEW5NS=>
CHLA-90 NGKyV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXHNVAh|ryP NXvGXlh3QTZiaB?= NImwZppFVVOR NXzKOppUUUN3ME2wMlA3OSEQvF2= M1jNcFIyPDR6NUmx
CHLA-119 NWPteIp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK2R45ZOTBizszN M2fLeVk3KGh? M3X0cWROW09? M3rEcWlEPTB;MD6wNlIh|ryP NIrkOGszOTR2OEW5NS=>
CHLA-122 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Xob|ExKM7:TR?= MmjoPVYhcA>? M4HRNGROW09? M2G0dGlEPTB;MD6wNVkh|ryP MV2yNVQ1QDV7MR?=
CHLA-136 MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[xNEDPxE1? NHrmZmg6PiCq NX;mUZpXTE2VTx?= MWTJR|UxRTBwMEO5JO69VQ>? MWKyNVQ1QDV7MR?=
CHLA-140 NVLuTpFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGxNEDPxE1? M3O1bFk3KGh? M1u1cmROW09? Mn3lTWM2OD1yLkCyOkDPxE1? M2TLZVIyPDR6NUmx
LA-N-6 NE[4eVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPHU4EyOCEQvF2= MWe5OkBp M3jVdGROW09? M1Pu[mlEPTB;MD6wOVQh|ryP MXuyNVQ1QDV7MR?=
NB-1643 NFS4PXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\4UGNmOTBizszN MUe5OkBp MXvEUXNQ NFnafFdKSzVyPUCuNFM4KM7:TR?= MYWyNVQ1QDV7MR?=
NB-EBc1 Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXOxNEDPxE1? MnnvPVYhcA>? MkXNSG1UVw>? M1rSO2lEPTB;MD6wOVAh|ryP MlXaNlE1PDh3OUG=
SK-N-BE-1 NVnZVnoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXYeHNnOTBizszN Ml3rPVYhcA>? MnnkSG1UVw>? NFW3SIZKSzVyPUCuNFI5KM7:TR?= MkHoNlE1PDh3OUG=
SK-N-BE-2 M{HDWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGxNEDPxE1? MUm5OkBp Mo\iSG1UVw>? NEC1[ppKSzVyPUCuNFM3KM7:TR?= MlOwNlE1PDh3OUG=
SMS-KAN NGTEPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvxNVAh|ryP NEDoco86PiCq MnXNSG1UVw>? NIrCSnpKSzVyPUCuNFM1KM7:TR?= M1HobFIyPDR6NUmx
SMS-KANR MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUOxNEDPxE1? NX3vdolTQTZiaB?= MXHEUXNQ NIG1[XlKSzVyPUCuNFI3KM7:TR?= M37qOFIyPDR6NUmx
SMS-KCN NW\Qb|RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHybncyOCEQvF2= MYi5OkBp MUnEUXNQ NFK1NIJKSzVyPUCuNFE6KM7:TR?= M1\3bFIyPDR6NUmx
SMS-KCNR NEHDUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL6No0yOCEQvF2= NWPkcZVoQTZiaB?= NYPJPZlpTE2VTx?= Mmn4TWM2OD1yLkCxNEDPxE1? NIjZdYUzOTR2OEW5NS=>
SMS-LHN NHLDbFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT2UppLOTBizszN MnX0PVYhcA>? M{K5cmROW09? MXLJR|UxRTBwMEOyJO69VQ>? M2rnfVIyPDR6NUmx
SMS-MSN MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUToSmhEOTBizszN MnfuPVYhcA>? Mm\uSG1UVw>? MVjJR|UxRTBwMEKyJO69VQ>? NHPQTpUzOTR2OEW5NS=>
SMS-SAN NWXR[VNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmxNEDPxE1? NFz2OGw6PiCq MoH2SG1UVw>? MlH6TWM2OD1yLkCyNEDPxE1? MWiyNVQ1QDV7MR?=
Granta-4 M4XBbGN6fG:2b4jpZ{BCe3OjeR?= Ml;nNVAh|ryP NVW2TFBQPyCm M3fUZmlEPTB;MD6wOFAh|ryP MUGyNVI6OTh4Nx?=
DB NVe0Zmt[S3m2b4TvfIlkKEG|c3H5 NEjPUmIyOCEQvF2= MX23JIQ> M1;vN2lEPTB;MD6wOFIh|ryP MlvRNlEzQTF6Nke=
RL Mn3LR5l1d3SxeHnjJGF{e2G7 M2LI[|ExKM7:TR?= MnXxO{Bl NGXJVHRKSzVyPUCuNFE2KM7:TR?= M4HjWlIyOjlzOE[3
K562 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;VfFExKM7:TR?= MVm5OkBp M4LubGlEPTB;MD6wPFch|ryP M3LXPVIyODlzNkOz
LAMA-84 M4foUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrifmt4OTBizszN MVy5OkBp NU\lT5E{UUN3ME2wMlA2PyEQvF2= NUTWNnFZOjFyOUG2N|M>
MM15 M1\RcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[0JO69VQ>? NV3ZbJc3PzJiaB?= NXH1PWhOTE2VTx?= M1f3W2lEPTB;MD6xN{DPxE1? M4DVbVIxOzh{OES0
OPM1 M3;pbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jwe|Qh|ryP MYe3NkBp NXSxVFRoTE2VTx?= NFr0RlJKSzVyPUCuNFMh|ryP M3rhblIxOzh{OES0
RPM1 Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHH[pQ1KM7:TR?= NWrK[ZlWPzJiaB?= NVW1V405TE2VTx?= M2HEOGlEPTB;MUCuN|Ih|ryP Mlm0NlA{QDJ6NES=
INA6 NUezXYJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Lkb|Qh|ryP M1fOOlczKGh? MoXCSG1UVw>? NGHGcmlKSzVyPUCuNFAzKM7:TR?= NE\6doszODN6Mki0OC=>
OPM2 MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\oSFJ3PCEQvF2= MUK3NkBp MkLMSG1UVw>? NXfZZmRMUUN3ME20MlM4KM7:TR?= NF3LO3QzODN6Mki0OC=>
MM1R NEixd4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;6dpI2PCEQvF2= MWe3NkBp M{izUmROW09? MYPJR|UxRTFwNkig{txO Mn;6NlA{QDJ6NES=
DOX40 M2\EVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLPOEDPxE1? NFfNZYw4OiCq MkfPSG1UVw>? Ml\STWM2OD13LkS4JO69VQ>? M{jPbFIxOzh{OES0
LR5 Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L6VVQh|ryP NU\PfIhkPzJiaB?= NVvpOZJiTE2VTx?= MULJR|UxRTJwNUOg{txO Mkn6NlA{QDJ6NES=
U266 M1\pNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV20JO69VQ>? MlizO|IhcA>? NInRZoVFVVOR NYr4Wng5UUN3ME2xMlQ{KM7:TR?= M{jqTlIxOzh{OES0
RD NG\1XlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPSNVAh|ryP MnvaPVYhcA>? MWjJR|UxRTBwMkK4JO69VQ>? M3LUV|IxOTB6M{O4
Rh41 Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrWZ4syOCEQvF2= NWqwe2lKQTZiaB?= NITUcGxKSzVyPUCuNFkxKM7:TR?= M3q3WlIxOTB6M{O4
Rh30 NF\rVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1m2b|ExKM7:TR?= M1XxVlk3KGh? NVq3b5NCUUN3ME2wMlI{OCEQvF2= NXOyd4xxOjBzMEizN|g>
BT-12 Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrENVAh|ryP NGD5WIo6PiCq NH;aVmVKSzVyPUCuNFYxKM7:TR?= MXuyNFExQDN|OB?=
CHLA-266 M{PBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LRTlExKM7:TR?= MnzZPVYhcA>? NHLMWoRKSzVyPUCuNFczKM7:TR?= MnHnNlAyODh|M{i=
TC-71 NXj0fG1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnmXXg{OTBizszN NWn4bHBDQTZiaB?= NXPZWmNtUUN3ME2wMlExOiEQvF2= Mn;CNlAyODh|M{i=
SJ-GBM2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm2Z21uOTBizszN NX60dYdSQTZiaB?= MmrZTWM2OD1yLkC1NEDPxE1? NEKw[5MzODFyOEOzPC=>
NALM-6 NEPFZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDpNVAh|ryP NVO0PWdoQTZiaB?= Mn7CTWM2OD1yLkC2NkDPxE1? Mn\INlAyODh|M{i=
COG-LL-317 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7USWoyOCEQvF2= M1zoelk3KGh? NIrCe4ZKSzVyPUCuNFQ4KM7:TR?= M3vDWVIxOTB6M{O4
RS4-11 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUexNEDPxE1? MkDaPVYhcA>? NVvrVlB3UUN3ME2wMlAyQCEQvF2= NV;3[4RyOjBzMEizN|g>
MOLT-4 Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;PdXMyOCEQvF2= NGPDeXA6PiCq NXHvNFlmUUN3ME2wMlAzPiEQvF2= MV[yNFExQDN|OB?=
CCRF-CEM MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PyPFExKM7:TR?= MYG5OkBp Mk[zTWM2OD1yLkC5OEDPxE1? Mn;qNlAyODh|M{i=
Kasumi-1 M1ixZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3L[plEOTBizszN NUm5SWV[QTZiaB?= Mn3zTWM2OD1yLkGwN{DPxE1? M3HKV|IxOTB6M{O4
Karpas-299 NWi5[mtvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7TRYVHOTBizszN MXO5OkBp NI[2NpRKSzVyPUCuNFM5KM7:TR?= MV6yNFExQDN|OB?=
Ramos-RA1 NUHJRWtRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MomzNVAh|ryP NV:1OVhsQTZiaB?= MnrlTWM2OD1yLkGyO{DPxE1? MYSyNFExQDN|OB?=

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay:[1]
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:[2]
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
15% Captisol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID